Tag Archives: GSK

Europe’s Fiscal Crisis: Can Big Pharma Emerge Unscathed?

By William Looney | Published: June 2, 2010
Europe’s current fiscal crisis, symbolized by the meltdown in Greece, is seen by big pharma as a temporary situation to be taken in stride—after all, the EU southern and eastern tier, with its chronically shaky finances and per capita incomes as low as a third of the EU norm, has historically been a marginal player [...]
Posted in Europe | Also tagged , , , , , | 2 Comments

Avandia Trial in Trouble

By Oriana Schwindt | Published: April 21, 2010
GSK’s Avandia just won’t stay out of the news. Now comes a report from The Wall Street Journal that the FDA is considering dealing the beleaguered diabetes drug another blow by stopping one of its safety trials. The TIDE trial, which received approval in 2007, pits Avandia (rosiglitazone) against Takeda’s Actos (pioglitazone), a drug that [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

FDA and GSK on the Hunt for Stolen Drugs

By George Koroneos | Published: February 24, 2010
Image by Johnny Grim via Flickr We typically don’t get emails from FDA  asking for information about stolen goods with massive bold letters, but that’s what just came into our inbox. Looks like a transport truck containing a mix of GlaxoSmithKline’s pharmaceutical and over-the-counter medications was jacked in Puerto Rico on January 29, and the feds [...]
Posted in FDA, News | Also tagged , , , , , | Leave a comment

HBA Names Woman of the Year

By Oriana Schwindt | Published: February 16, 2010
GSK’s Deirdre Connelly has been named the Healthcare Businesswomen’s Association’s Woman of the Year for 2010. Connelly, who just passed the one-year mark as president of GSK’s North American pharmaceuticals unit, is the 21st woman to win the organization’s “WOTY” award, which comes on the heels of another honor: She was ranked #37 in Fortune’s [...]
Posted in Corporate Responsibility, News, People, leadership | Also tagged , , , | Leave a comment

A Few Words About Diversification

By Julian Upton | Published: February 1, 2010
Guest blog by Dr Brian White, an analyst at Shore Capital. As a result of the feared impact of the patent expiry cliff, the decimation of branded sales by multi-sourced generics and the obstacles erected, especially by managed care in the US, to slow the uptake of branded pharmaceuticals where a generic in the same class [...]
Posted in Europe, Global, Guest Blog, Strategy | Also tagged , , , , , | Leave a comment